�ݺ�ߣshows by User: JimBRegan

�ݺ�ߣshows by User: JimBRegan / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: JimBRegan / Sun, 22 Mar 2015 07:19:48 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: JimBRegan Huntingdon powerpoint /slideshow/huntingdon-powerpoint/46134546 huntingdonpowerpoint-150322071949-conversion-gate01
HUntingdon Life Sciences | Harlan Laboratories]]>
HUntingdon Life Sciences | Harlan Laboratories]]> Sun, 22 Mar 2015 07:19:48 GMT /slideshow/huntingdon-powerpoint/46134546 JimBRegan@slideshare.net(JimBRegan) Huntingdon powerpoint JimBRegan HUntingdon Life Sciences | Harlan Laboratories <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/huntingdonpowerpoint-150322071949-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> HUntingdon Life Sciences | Harlan Laboratories

Huntingdon powerpoint from Jim Regan

]]> 416 4 https://cdn.slidesharecdn.com/ss_thumbnails/huntingdonpowerpoint-150322071949-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 EDSP webinar 3: In vivo assays for the EDSP /slideshow/edsp-webinar-3-in-vivo-assays-web/30798098 edspwebinar3-invivoassays-web-140204073922-phpapp02
The science and methodologies required to perform the Endocrine Disruptor Screening Program’s Tier 1 In Vivo Mammalian Assays will be discussed including the nature of the reproductive and general toxicity endpoints and the alterations that may signal endocrine disruption. As the Male and Female Pubertal studies can be performed as a Combined Male and Female Pubertal Study, the advantages and disadvantages of the combined assay will also be discussed. Regulatory agencies have consistently agreed that endocrine disruption must be evaluated by “Weight of Evidence” (WoE) procedures. A discussion of the relative weight for each endpoint and the use of the hypothesis-based “WoE” approach for determination a positive response in this assay will be discussed. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]>
The science and methodologies required to perform the Endocrine Disruptor Screening Program’s Tier 1 In Vivo Mammalian Assays will be discussed including the nature of the reproductive and general toxicity endpoints and the alterations that may signal endocrine disruption. As the Male and Female Pubertal studies can be performed as a Combined Male and Female Pubertal Study, the advantages and disadvantages of the combined assay will also be discussed. Regulatory agencies have consistently agreed that endocrine disruption must be evaluated by “Weight of Evidence” (WoE) procedures. A discussion of the relative weight for each endpoint and the use of the hypothesis-based “WoE” approach for determination a positive response in this assay will be discussed. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]> Tue, 04 Feb 2014 07:39:22 GMT /slideshow/edsp-webinar-3-in-vivo-assays-web/30798098 JimBRegan@slideshare.net(JimBRegan) EDSP webinar 3: In vivo assays for the EDSP JimBRegan The science and methodologies required to perform the Endocrine Disruptor Screening Program’s Tier 1 In Vivo Mammalian Assays will be discussed including the nature of the reproductive and general toxicity endpoints and the alterations that may signal endocrine disruption. As the Male and Female Pubertal studies can be performed as a Combined Male and Female Pubertal Study, the advantages and disadvantages of the combined assay will also be discussed. Regulatory agencies have consistently agreed that endocrine disruption must be evaluated by “Weight of Evidence” (WoE) procedures. A discussion of the relative weight for each endpoint and the use of the hypothesis-based “WoE” approach for determination a positive response in this assay will be discussed. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar3-invivoassays-web-140204073922-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds" /> The science and methodologies required to perform the Endocrine Disruptor Screening Program’s Tier 1 In Vivo Mammalian Assays will be discussed including the nature of the reproductive and general toxicity endpoints and the alterations that may signal endocrine disruption. As the Male and Female Pubertal studies can be performed as a Combined Male and Female Pubertal Study, the advantages and disadvantages of the combined assay will also be discussed. Regulatory agencies have consistently agreed that endocrine disruption must be evaluated by “Weight of Evidence” (WoE) procedures. A discussion of the relative weight for each endpoint and the use of the hypothesis-based “WoE” approach for determination a positive response in this assay will be discussed. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars

EDSP webinar 3: In vivo assays for the EDSP from Jim Regan

]]> 1050 6 https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar3-invivoassays-web-140204073922-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 EDSP webinar 1: Background, lesson learned and the future /slideshow/edsp-webinar-1-background-lesson-learned-and-the-future/30798081 edspwebinar1-edspbackground-web-140204073856-phpapp01
This webinar will review the importance of the endocrine system for human health; EPA's regulatory history of how the current testing program developed; lessons learned from providing OSRI (Other Scientific Relevant Information) in response to Tier 1 Test Orders; conducting Tier 1 screens; and, integrating Tier 1 screening data with OSRI to generate Weight of Evidence documents that speak to whether further testing (Tier 2 studies) are needed and appropriate. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]>
This webinar will review the importance of the endocrine system for human health; EPA's regulatory history of how the current testing program developed; lessons learned from providing OSRI (Other Scientific Relevant Information) in response to Tier 1 Test Orders; conducting Tier 1 screens; and, integrating Tier 1 screening data with OSRI to generate Weight of Evidence documents that speak to whether further testing (Tier 2 studies) are needed and appropriate. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]> Tue, 04 Feb 2014 07:38:56 GMT /slideshow/edsp-webinar-1-background-lesson-learned-and-the-future/30798081 JimBRegan@slideshare.net(JimBRegan) EDSP webinar 1: Background, lesson learned and the future JimBRegan This webinar will review the importance of the endocrine system for human health; EPA's regulatory history of how the current testing program developed; lessons learned from providing OSRI (Other Scientific Relevant Information) in response to Tier 1 Test Orders; conducting Tier 1 screens; and, integrating Tier 1 screening data with OSRI to generate Weight of Evidence documents that speak to whether further testing (Tier 2 studies) are needed and appropriate. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar1-edspbackground-web-140204073856-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds" /> This webinar will review the importance of the endocrine system for human health; EPA's regulatory history of how the current testing program developed; lessons learned from providing OSRI (Other Scientific Relevant Information) in response to Tier 1 Test Orders; conducting Tier 1 screens; and, integrating Tier 1 screening data with OSRI to generate Weight of Evidence documents that speak to whether further testing (Tier 2 studies) are needed and appropriate. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars

EDSP webinar 1: Background, lesson learned and the future from Jim Regan

]]> 382 3 https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar1-edspbackground-web-140204073856-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 EDSPwebinar 4: The amphibian metamorphosis assay /JimBRegan/edsp-webinar-4-amphibian-metamorphosis-assay-web edspwebinar4-amphibianmetamorphosisassay-web-140204073825-phpapp01
Amphibians are considered as being exceptionally vulnerable to endocrine disrupters, as they exhibit obvious effects on limb development and metamorphosis in wild populations following exposure. They have a high degree of sensitivity, whether in the tadpole stage or as adults, and respond to seemingly minimal changes in the environment. This webinar discusses the metamorphosis assay, the selection of Xenopus Laevis, some aspects of the study design and where improvements could be made. We also discuss what the study means for you and how you can ensure that your contractor has all they need to conduct the study successfully. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]>
Amphibians are considered as being exceptionally vulnerable to endocrine disrupters, as they exhibit obvious effects on limb development and metamorphosis in wild populations following exposure. They have a high degree of sensitivity, whether in the tadpole stage or as adults, and respond to seemingly minimal changes in the environment. This webinar discusses the metamorphosis assay, the selection of Xenopus Laevis, some aspects of the study design and where improvements could be made. We also discuss what the study means for you and how you can ensure that your contractor has all they need to conduct the study successfully. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]> Tue, 04 Feb 2014 07:38:25 GMT /JimBRegan/edsp-webinar-4-amphibian-metamorphosis-assay-web JimBRegan@slideshare.net(JimBRegan) EDSPwebinar 4: The amphibian metamorphosis assay JimBRegan Amphibians are considered as being exceptionally vulnerable to endocrine disrupters, as they exhibit obvious effects on limb development and metamorphosis in wild populations following exposure. They have a high degree of sensitivity, whether in the tadpole stage or as adults, and respond to seemingly minimal changes in the environment. This webinar discusses the metamorphosis assay, the selection of Xenopus Laevis, some aspects of the study design and where improvements could be made. We also discuss what the study means for you and how you can ensure that your contractor has all they need to conduct the study successfully. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar4-amphibianmetamorphosisassay-web-140204073825-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Amphibians are considered as being exceptionally vulnerable to endocrine disrupters, as they exhibit obvious effects on limb development and metamorphosis in wild populations following exposure. They have a high degree of sensitivity, whether in the tadpole stage or as adults, and respond to seemingly minimal changes in the environment. This webinar discusses the metamorphosis assay, the selection of Xenopus Laevis, some aspects of the study design and where improvements could be made. We also discuss what the study means for you and how you can ensure that your contractor has all they need to conduct the study successfully. More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars

EDSPwebinar 4: The amphibian metamorphosis assay from Jim Regan

]]> 2358 8 https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar4-amphibianmetamorphosisassay-web-140204073825-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 EDSP webinar 2: In vitro assays for the EDSP /slideshow/edsp-webinar-2-in-vitro-assays-web/30798033 edspwebinar2-invitroassays-web-140204073746-phpapp02
This webinar discusses the in vitro studies required for the EPA’s Endocrine Disruptor Screening Program; we will take a closer look at each of studies, their challenges, their endpoints, their acceptance criteria and discuss our experience of the validation of the assays. We will also look at some ways in which you can ensure that your studies run smoothly and efficiently. We will close out by discussing the EDSP’s Data Evaluation Record (DER) and the Standard Evaluation Procedures (SEP). More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]>
This webinar discusses the in vitro studies required for the EPA’s Endocrine Disruptor Screening Program; we will take a closer look at each of studies, their challenges, their endpoints, their acceptance criteria and discuss our experience of the validation of the assays. We will also look at some ways in which you can ensure that your studies run smoothly and efficiently. We will close out by discussing the EDSP’s Data Evaluation Record (DER) and the Standard Evaluation Procedures (SEP). More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars]]> Tue, 04 Feb 2014 07:37:46 GMT /slideshow/edsp-webinar-2-in-vitro-assays-web/30798033 JimBRegan@slideshare.net(JimBRegan) EDSP webinar 2: In vitro assays for the EDSP JimBRegan This webinar discusses the in vitro studies required for the EPA’s Endocrine Disruptor Screening Program; we will take a closer look at each of studies, their challenges, their endpoints, their acceptance criteria and discuss our experience of the validation of the assays. We will also look at some ways in which you can ensure that your studies run smoothly and efficiently. We will close out by discussing the EDSP’s Data Evaluation Record (DER) and the Standard Evaluation Procedures (SEP). More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar2-invitroassays-web-140204073746-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds" /> This webinar discusses the in vitro studies required for the EPA’s Endocrine Disruptor Screening Program; we will take a closer look at each of studies, their challenges, their endpoints, their acceptance criteria and discuss our experience of the validation of the assays. We will also look at some ways in which you can ensure that your studies run smoothly and efficiently. We will close out by discussing the EDSP’s Data Evaluation Record (DER) and the Standard Evaluation Procedures (SEP). More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars

EDSP webinar 2: In vitro assays for the EDSP from Jim Regan

]]> 881 2 https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar2-invitroassays-web-140204073746-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-JimBRegan-48x48.jpg?cb=1519822982 I am a marketing manager with a great interest in the digital landscape and the platforms available to us today and am always looking at how I can develop and exploit these opportunities for our company. Content creation is a passion of mine; reflected in my work with our company website and in-house scientific journal. I believe that the old adage that Content is King has never been more true than it is in today’s content-driven, inbound marketing environment. I am experienced in project management (Prince2 Practitioner) and believe that projects work best when people are fully engaged – one of the reasons why I studied for a Level 5 Coaching and Mentoring Award. Results • Cor... http://www.huntingdon.com https://cdn.slidesharecdn.com/ss_thumbnails/huntingdonpowerpoint-150322071949-conversion-gate01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/huntingdon-powerpoint/46134546 Huntingdon powerpoint https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar3-invivoassays-web-140204073922-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/edsp-webinar-3-in-vivo-assays-web/30798098 EDSP webinar 3: In viv... https://cdn.slidesharecdn.com/ss_thumbnails/edspwebinar1-edspbackground-web-140204073856-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/edsp-webinar-1-background-lesson-learned-and-the-future/30798081 EDSP webinar 1: Backgr...